Navigation Links
Decision Biomarkers Inc Announces Formation of Scientific Advisory Board
Date:12/2/2008

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Biomarkers Inc, a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the formation of a Scientific Advisory Board consisting of internationally renowned scientists and physicians at the forefront of biomarker and clinical research. The Scientific Advisory Board includes:

-- Daniel W. Chan, Ph.D., Director of the Center for Biomarker Discovery and Director, Clinical Chemistry Division, at Johns Hopkins Medical Institution. In addition to his responsibilities of heading the hospital clinical chemistry laboratory, Dr. Chan conducts cutting edge research using state of the art proteomic techniques for biomarker discovery. His overall goals are the identification and characterization of novel biomarkers for the diagnosis and treatment of cancer.

-- Johann de Bono, M.D., Ph.D., Senior Lecturer at The Institute for Cancer Research, Royal Marsden Hospital. Dr. de Bono is leader of the Prostate Cancer Team and directs the clinical drug development Phase I trials program at Royal Marsden Hospital, with a particular interest in pharmacokinetic - pharmacodynamic evaluation of targeted therapeutics.

-- John Heymach, M.D., Ph.D., Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. The goal of Dr. Heymach's clinical, translational and laboratory research is to advance the development of targeted agents, particularly angiogenesis inhibitors for non-small lung cancer, by incorporating biomarkers into clinical trials to improve patient outcomes.

-- Peter Maimonis, Ph.D. Vice President of Biological Research, Decision Biomarkers, Waltham, MA. Dr. Maimonis has been involved in the discovery and validation of tumor biomarkers for over 20 years. His research has focused on diagnostic markers for breast and colorectal cancer. He has also developed assays for many of these biomarkers, taking a number of them through FDA approval.

-- Larry Oliver, Ph.D., Scientific Director of Mayo Clinical Trial Services and Director of the Metals Laboratory in the Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, MN. Dr. Oliver's research includes performance definitions of surrogate biomarkers of efficacy, antibody-antigen binding characterization, and clinical and analytical validation of biomarkers of safety.

"We are extremely pleased to have recruited such an outstanding group of visionary thought leaders to our SAB", said Roger Dowd, President and CEO of DBI. "We look forward to their expert guidance to enable us to realize the full potential of our multiplex immunoassay technology for drug development". About Decision Biomarkers Inc Decision Biomarkers is a privately-held life science tools company that has developed the next-generation technology for protein biomarker analysis. DBI is driving productivity improvement in the pharmaceutical and diagnostic industries by supplying automated, multiplex protein biomarker systems that can be used by virtually anyone, anywhere and in real time.

www.decisionbiomarkers.com


'/>"/>
SOURCE Decision Biomarkers Inc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
2. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
5. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
8. Scientists Using Social Media to Inform Lab Purchasing Decisions
9. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
10. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea monster her father ... found a sea turtle entangled in the lines of one of his lobster pots. He ... because no one could remember ever seeing one so large so close to shore. After ...
(Date:12/6/2016)... Texas , Dec. 6, 2016 The ... for its adoption of arnica ( Arnica montana ... support to ABC,s HerbMedPro database, a ... important scientific and clinical research data on the ... popular herbs. Naturopathica, a wellness company ...
(Date:12/6/2016)... 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... quarter and fiscal year ended September 30, 2016. ... , , ... and diagnostics company that develops and commercializes proprietary technologies and products ... Achieved revenues of $1.4 million more than tripling prior years ...
(Date:12/6/2016)... PA (PRWEB) , ... December ... ... part of the Almac Group, the world’s largest privately-held contract pharmaceutical development ... with inVentiv Health, a leading biopharma outsourcing company combining a leading CRO ...
Breaking Biology Technology:
(Date:12/6/2016)... Ind. , Dec. 6, 2016  Zimmer Biomet Holdings, ... it has priced an offering of €500.0 million principal amount ... million principal amount of its 2.425% senior unsecured notes due ... expected to occur on December 13, 2016, subject to the satisfaction ... an annual basis. The ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):